Figure 8. Compared with CH58, the newly identified V2-specific mAbs exhibit increased ADCC breadth against RV144 breakthrough virus IMC-infected CD4⁺ T cells.

A subset of linear peptide–binding and conformational dependent V2-specific mAbs were assayed for ADCC against a panel of 11 different RV144 breakthrough virus IMC-infected target cells. CH58 and CH59 responses are shown in red, and the newly characterized RV305 V2 mAb responses are shown in black. Data are expressed as mean ADCC endpoint concentration (μg/mL) per antibody from 2 independent experiments.